With increasing lines of therapy, there may be increased expression of MDR-1 [32], in particular carfilzomib-resistant multiple myeloma cells show a strong up-regulation of MDR-1 [33,34]. This evidence concerns the gene ABCB1 and plasma cell myeloma.